Photo courtesy of Mylan
Sanofi and Genzyme have filed a complaint against Mylan for patent infringement over the drug Aubagio (teriflunomide), a treatment for relapsing forms of multiple sclerosis.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Mylan, Sanofi, Genzyme, patent, Aubagio
